OPA1 and pulmonary arterial hypertension: Thus, by simultaneously leveraging the newly-identified anti-inflammatory and well-known vasodilatory properties of NTG, such smart nanomedicine approaches may provide a superior therapeutic strategy for effective management of PAH that is characterized by both chronic pulmonary arterial inflammation and vasoconstriction35.